This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Apricus Biosciences Announces Poster Presentation Of Vitaros(R) Data In Men Previously Unresponsive To PDE-5 Inhibitors At American Urological Association Annual Meeting

SAN DIEGO, May 7, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) ( announced today that John P. Mulhall, MD, Director of the Male Sexual and Reproductive Medicine Program at Memorial Sloan-Kettering Cancer Center, will present results from an analysis of existing Phase 3 data for Vitaros®, the Company's lead product candidate for the treatment of erectile dysfunction (ED), at the American Urological Association Annual Meeting which is taking place May 4-8, 2013 in San Diego, CA.

The abstract titled, "Vitaros ® Efficacy and Safety in Viagra ® Non-Responders with Longer Term Use," will be presented as a moderated poster (#1519) during a session titled "Sexual Function/Dysfunction/Andrology: Medical and Non-Surgical Therapy," taking place Tuesday, May 7, 2013 from 8-10 a.m. local time. Dr. Mulhall will give a short oral presentation, which will then be followed by a question and answer period.

This analysis evaluated the safety and efficacy of Vitaros ® after 12 weeks, and longer term use, in men previously unresponsive to phosphodiesterase type 5 (PDE-5) inhibitors, such as Viagra ® (n=325). Results showed that 200mcg and 300mcg doses of Vitaros® improved erections in this population and adverse events (AE) were mild to moderate, similar to those seen in the control group, and decreased with repeated exposure.

"PDE-5 inhibitors, while effective, address only a portion of the ED patient population. In the current treatment landscape, this leaves a large population of unresponsive or contraindicated patients with few or no alternatives," said Dr. John Mulhall, lead author and Director of the Male Sexual and Reproductive Medicine Program at Memorial Sloan-Kettering Cancer Center. "Vitaros ® utilizes a novel mechanism of action that has demonstrated successful ED therapy without the side effects associated with current products, making it an effective and practical option for these patients."

Dr. Mulhall is also an Associate Editor for the Journal of Sexual Medicine and past President of the Sexual Medicine Society of North America.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.18 1.64%
FB $117.44 -0.95%
GOOG $692.33 -0.84%
TSLA $232.32 -3.92%
YHOO $36.02 -1.40%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs